Evidence map›Paper›PMID 39008138›Full record

ArticleJournal of cancer survivorship : research and practice2026

Association of cancer treatment with excess heart age among five-year young breast cancer survivors.

Jacqueline B Vo, Shoshana Rosenberg, Bessie X Zhang, Craig Snow, Greg Kirkner, Philip D Poorvu, Rachel Gaither, Kathryn J Ruddy, Rulla M Tamimi, Jeffrey M Peppercorn and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jacqueline B VoCancer Prevention Fellowship Program, Division of Cancer Epidemiology & Genetics, National Cancer Institute, 9609 Medical Center Drive, 7E532, Bethesda, Rockville, MD, 20906, USA. jacqueline.vo@nih.gov.
Shoshana RosenbergDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Bessie X ZhangHarvard Medical School, Boston, MA, USA.
Craig SnowDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Greg KirknerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Philip D PoorvuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rachel GaitherDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kathryn J RuddyDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Rulla M TamimiDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Jeffrey M PeppercornDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Lidia SchapiraDepartment of Medicine, Stanford Cancer Institute, Palo Alto, CA, USA.
Virginia F BorgesDivision of Medical Oncology, University of Colorado Cancer Center, Aurora, CO, USA.
Steven E ComeDepartment of Medicine, Breast Oncology Program, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Anju NohriaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ann H PartridgeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeData evaluating cardiovascular disease (CVD) risk by cancer treatment among young women (≤ 40 years) with breast cancer are limited.

methodsAmong 372 five-year breast cancer survivors aged 30-40 years from the Young Women's Breast Cancer Study, we assessed the association of cancer treatments (anthracyclines, trastuzumab, radiation/laterality, endocrine therapy) and excess heart age (difference between predicted 10-year CVD risk as assessed by adapted Framingham Risk Score and chronological age), prevalent elevated excess heart age (≥ 2 years), and worsening excess heart age (change of ≥ 2 excess heart age years) at breast cancer diagnosis and two- and five-year follow-up using multivariable linear and logistic regressions.

resultsMost women had stage I or II (79%), ER + (71%), or PR + (65%) breast cancer. At diagnosis, women had little excess heart age by treatment receipt (range of means = -0.52,0.91 years). Left-sided radiation (β = 2.49,SE = 0.96,p = 0.01) was associated with higher excess heart age at five-year follow-up. For prevalent elevated excess heart age (two-year = 26%;five-year = 27%), women treated with right-sided radiation had increased risk at two-years (OR = 2.17,95%CI = 1.12-4.19), yet at five-years, associations were observed after any radiation (OR = 1.92,95%CI = 1.09-3.41), especially after left-sided (OR = 2.13,95%CI = 1.09-3.41) radiation. No associations were observed between systemic treatments and prevalent elevated excess heart age or any treatments with worsening excess heart age.

conclusionsAmong young breast cancer survivors, radiation, but not other cancer treatments, was associated with elevated excess heart age. IMPLICATIONS FOR CANCER SURVIVORS: CVD risk tools that incorporate cancer treatment, such as radiation, are needed to identify high risk young breast cancer survivors given the long survivorship and long latency of cardiovascular disease.

Indexed as

Breast NeoplasmsCancer SurvivorsCardiovascular DiseasesAdultFemaleFollow-Up StudiesHumansBreast cancer survivorshipCardiovascular disease riskExcess heart ageYoung breast cancer

Identifiers

PMID39008138
PMCPMC12906554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.